報價延遲最少15分鐘:2025/06/06 01:15 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
48.83 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.30/-3.15
|
|
企業價值
3.24B
|
| 資產負債 |
|
每股賬面淨值
6.42
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/06 01:15 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. |